| Nov 15 |
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
|
| Nov 7 |
aTyr Pharma GAAP EPS of -$0.23 misses by $0.01
|
| Nov 7 |
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
|
| Oct 24 |
aTyr Pharma: The Bull Has Finally Come Out
|
| Oct 24 |
High Growth Tech Stocks to Watch in October 2024
|
| Oct 14 |
aTyr Pharma to Present at the LD Micro Main Event XVII in October
|
| Oct 8 |
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
|
| Oct 2 |
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
|
| Sep 9 |
aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point
|
| Sep 5 |
aTyr started at buy by Jefferies, citing efzofitimod potential
|
